The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Non-engineered multiantigen-targeted T-cells in patients with lymphoma
Spyridoula Vasileiou, PhD, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, discusses the findings of an investigation evaluating an autologous T-cell product that targets multiple tumor-associated antigens expressed by lymphomas with the intent of treated disease and preventing immune escape in patients with chemorefractory lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
